NCCN Guidelines® Insights: B-cell lymphomas, version 6.2023 Guidelines
| Authors: | Zelenetz, A. D.; Gordon, L. I.; Abramson, J. S.; Advani, R. H.; Andreadis, B.; Bartlett, N. L.; Budde, L. E.; Caimi, P. F.; Chang, J. E.; Christian, B.; DeVos, S.; Dholaria, B.; Fayad, L. E.; Habermann, T. M.; Hamid, M. S.; Hernandez-Ilizaliturri, F.; Hu, B.; Kaminski, M. S.; Karimi, Y.; Kelsey, C. R.; King, R.; Krivacic, S.; LaCasce, A. S.; Lim, M.; Messmer, M.; Narkhede, M.; Rabinovitch, R.; Ramakrishnan, P.; Reid, E.; Roberts, K. B.; Saeed, H.; Smith, S. D.; Svoboda, J.; Swinnen, L. J.; Tuscano, J.; Vose, J. M.; Dwyer, M. A.; Sundar, H. |
| Title: | NCCN Guidelines® Insights: B-cell lymphomas, version 6.2023 |
| Abstract: | Novel targeted therapies (small molecule inhibitors, antibody-drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas. Bruton's tyrosine kinase (BTK) inhibitors continue to evolve in the management of mantle cell lymphoma (MCL), in both the relapsed/refractory and the frontline setting. Anti-CD19 CAR T-cell therapies are now effective and approved treatment options for relapsed/refractory follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and MCL. Bispecific T-cell engagers represent a novel immunotherapeutic approach for relapsed FL and DLBCL after multiple lines of therapies, including prior CAR T-cell therapy. These NCCN Guideline Insights highlight the significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, DLBCL, and MCL. |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 21 |
| Issue: | 11 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2023-11-01 |
| Start Page: | 1118 |
| End Page: | 1131 |
| Language: | English |
| DOI: | 10.6004/jnccn.2023.0057 |
| PUBMED: | 37935098 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work